NCT04233567View on ClinicalTrials.gov

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2025

Conditions
Advanced Malignant Solid NeoplasmCholangiocarcinomaMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
Interventions
DRUG

Infigratinib

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Sameek Roychowdhury

OTHER

NCT04233567 - Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | Biotech Hunter | Biotech Hunter